A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

• Status: Completed
• Trial end date: 2017-03-14
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda

Criteria

Inclusion Criteria:

• The participant has completed the preceding study.

• The participant has shown no safety issues during the study treatment in the preceding study, in the opinion of the investigator or subinvestigator.

Exclusion Criteria:

• The participant has undergone blood collection of >= 400 mL within 90 days prior to the start of treatment in this study.

• The participant is required to take any of the excluded medications or treatments.

• The participant is required surgery or hospitalization for surgery during the study period.